Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Nantero Announces Licensing to Alpha Szenszor, Inc.

Abstract:
Start up Developing Portable and Cost-effective Detectors for Infectious Diseases Including HIV.

Nantero Announces Licensing to Alpha Szenszor, Inc.

WOBURN, MA | Posted on June 26th, 2007

Nantero, Inc., a nanotechnology company using carbon nanotubes for the development of next-generation semiconductor devices, has provided license rights for biomedical sensors to Alpha Szenszor, Inc., a newly-formed company also based in Woburn, Massachusetts. Alpha Szenszor is developing a suite of sensor products in the medical field, including portable and cost-effective detectors for infectious diseases such as HIV. Alpha Szenszor's co-founders include Steve Lerner, an industry veteran with over 28 years of product development and industrialization experience, and Professor Charles Lieber of Harvard University, world-renowned expert in the field of nanobio sensors.

Nantero's intellectual property includes over 100 patent applications, of which over 25 have already been granted. This intellectual property portfolio is centered around the use of carbon nanotubes in mass manufacturing environments to make a variety of products, including Nantero's NRAM™, a high-density nonvolatile random access memory device. In addition to its work developing NRAM, Nantero is actively licensing its intellectual property portfolio to both startups and established companies for the development of other products that incorporate carbon nanotubes.

Alpha Szenszor is developing a biomedical sensor platform for applications in the field of disease diagnostics and personalized medicine. These products will allow testing of a wide range of diseases such as Cold and Flu, Cancer, Heart Disease, Sexually Transmitted Infections, Food Contamination, and the presence of other life threatening disorders. Alpha Szenszor technology will eliminate the costly and time consuming procedures associated with current diagnostics technology.

Steve Lerner, CEO and Co-Founder of Alpha Szenszor, said, "With our world-class team combining experts in health care, semiconductor processing, and Nantero's scalable carbon nanotube technology, we are poised to bring revolutionary products to market in a very short time frame. We will enable portable disease testing that would be available through local pharmacies and allow anyone to test themselves with total privacy and at a low cost. When placed in the hands of the primary care physicians, we envision our technology becoming part of every patient check-up."

Professor Charles Lieber, Co-Founder of Alpha Szenszor, added, "The Nantero technology provides a highly industrialized platform through which my years of work may be applied to facilitate this revolution in global health care."

Greg Schmergel, CEO and Co-Founder of Nantero noted "Nantero is approached frequently for licenses to its intellectual property for various fields of use, and we have to pick carefully the right partners who have the capability to bring products to market that will add substantial value to their customers. We believe Alpha Szenszor is such a partner and look forward to working with them."

####

About Nantero, Inc.
Nantero is a nanotechnology company using carbon nanotubes for the development of next-generation semiconductor devices. Nantero’s main focus is the development of NRAM™. Nantero is also working with licensees on the development of additional applications of Nantero’s core nanotube-based technology.

More information on Nantero, Inc. is available in English and Japanese at http://www.nantero.com

About Alpha Szenszor

Alpha Szenszor a point of care molecular diagnostics chip company. Alpha Szenszor’s products allow real time, label free detection and quantification of proteins and nucleic acids in a highly scaleable and cost effect platform. Most importantly the company ushers in a digital alternative to current optically based diagnostics. Alpha Szenszor is in the process of raising series A funds, and has already garnered the endorsement of several industry leaders.

For more information, please click here

Contacts:
Nantero, Inc.
Suzanne Gibbons-Neff, 617-670-1763

or
Alpha Szenszor Inc., 978-371-7084
Fax: 978-371-7579

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024

Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

Announcements

NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024

Innovative sensing platform unlocks ultrahigh sensitivity in conventional sensors: Lan Yang and her team have developed new plug-and-play hardware to dramatically enhance the sensitivity of optical sensors April 5th, 2024

Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024

A simple, inexpensive way to make carbon atoms bind together: A Scripps Research team uncovers a cost-effective method for producing quaternary carbon molecules, which are critical for drug development April 5th, 2024

Patents/IP/Tech Transfer/Licensing

Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023

Study finds nanomedicine targeting lymph nodes key to triple negative breast cancer treatment: In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cance May 13th, 2022

Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project